CSNpharm

CSNpharm logo

Csnpharm is committed to providing you with high quality products and outstanding services. We supply over 5000 bioactive compounds in stock, including inhibitors, agonists and natural products for laboratory and scientific use. Csnpharm has always been committed to develop quality products that are validated by NMR, UPLC, LC-MS, GC, Chiral HPLC and so on. We have a professional technical support team for customer service with years of experience in life science. Csnpharm is your reliable partner for scientific research.

Company Website

Product Listing

ML 213 10mg  | ≥98%

CSNpharm

ML213 is an activator of Kv7.2 (KCNQ2) and Kv7.4 (KCNQ4) channels with EC50s of 230 and 510 nM respectively.

More Information Supplier Page

ML 213 100mg  | ≥98%

CSNpharm

ML213 is an activator of Kv7.2 (KCNQ2) and Kv7.4 (KCNQ4) channels with EC50s of 230 and 510 nM respectively.

More Information Supplier Page

ML 213 50mg  | ≥98%

CSNpharm

ML213 is an activator of Kv7.2 (KCNQ2) and Kv7.4 (KCNQ4) channels with EC50s of 230 and 510 nM respectively.

More Information Supplier Page

ML 213 5mg  | ≥98%

CSNpharm

ML213 is an activator of Kv7.2 (KCNQ2) and Kv7.4 (KCNQ4) channels with EC50s of 230 and 510 nM respectively.

More Information Supplier Page

ML 213 25mg  | ≥98%

CSNpharm

ML213 is an activator of Kv7.2 (KCNQ2) and Kv7.4 (KCNQ4) channels with EC50s of 230 and 510 nM respectively.

More Information Supplier Page

ML-180 5mg  | ≥98%

CSNpharm

ML-180 (SR1848) is a potent orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) inverse agonist with an IC50 of 3.7 µM. ML-180 is inactive for steroidogenic factor-1 (SF-1; NR5A1; IC50>10 µM). ML-180 has the potential for LRH-1-dependent cancers .

More Information Supplier Page

ML-180 10mg  | ≥98%

CSNpharm

ML-180 (SR1848) is a potent orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) inverse agonist with an IC50 of 3.7 µM. ML-180 is inactive for steroidogenic factor-1 (SF-1; NR5A1; IC50>10 µM). ML-180 has the potential for LRH-1-dependent cancers .

More Information Supplier Page

ML-180 100mg  | ≥98%

CSNpharm

ML-180 (SR1848) is a potent orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) inverse agonist with an IC50 of 3.7 µM. ML-180 is inactive for steroidogenic factor-1 (SF-1; NR5A1; IC50>10 µM). ML-180 has the potential for LRH-1-dependent cancers .

More Information Supplier Page

ML-180 50mg  | ≥98%

CSNpharm

ML-180 (SR1848) is a potent orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) inverse agonist with an IC50 of 3.7 µM. ML-180 is inactive for steroidogenic factor-1 (SF-1; NR5A1; IC50>10 µM). ML-180 has the potential for LRH-1-dependent cancers .

More Information Supplier Page

ML-7 HCl 50mg  | ≥99%

CSNpharm

ML-7 HCl is a multiple-target inhibitor of MLCK with Ki value of 300 nM, PKA with 21μM, and PKC of 42 μM.

More Information Supplier Page

ML-7 HCl 10mg  | ≥99%

CSNpharm

ML-7 HCl is a multiple-target inhibitor of MLCK with Ki value of 300 nM, PKA with 21μM, and PKC of 42 μM.

More Information Supplier Page

ML-7 HCl 5mg  | ≥99%

CSNpharm

ML-7 HCl is a multiple-target inhibitor of MLCK with Ki value of 300 nM, PKA with 21μM, and PKC of 42 μM.

More Information Supplier Page

ML-9 250mg  | ≥99%

CSNpharm

ML 9 a is myosin light chain kinase (MLCK) inhibitor. ML-9 enhances the anticancer activity of docetaxel, suggesting its potential application as an adjuvant to existing anticancer chemotherapy. The complex effect of ML-9 on autophagy and indentified ML-9 as an attractive tool for targeting autophagy in cancer therapy through dual inhibition of both the Akt […]

More Information Supplier Page

ML133 HCl 50mg  | ≥99%

CSNpharm

ML133 HCl selectively inhibit Kir2.1 with IC50 of 1.8 μM at pH7.4 and 290 nM at pH8.5 and has no effect on Kir1.1 and weak activity for Kir4.1 and Kir7.1.

More Information Supplier Page

ML133 HCl 100mg  | ≥99%

CSNpharm

ML133 HCl selectively inhibit Kir2.1 with IC50 of 1.8 μM at pH7.4 and 290 nM at pH8.5 and has no effect on Kir1.1 and weak activity for Kir4.1 and Kir7.1.

More Information Supplier Page

ML133 HCl 10mg  | ≥99%

CSNpharm

ML133 HCl selectively inhibit Kir2.1 with IC50 of 1.8 μM at pH7.4 and 290 nM at pH8.5 and has no effect on Kir1.1 and weak activity for Kir4.1 and Kir7.1.

More Information Supplier Page

ML171 100mg  | ≥98%

CSNpharm

ML171 is a novel and selective NOX1 inhibitor with IC50 value of 0.25 μM for blocking NOX1-dependent ROS generation in a HEK293-NOX1 recombinant cell system.

More Information Supplier Page

ML171 25mg  | ≥98%

CSNpharm

ML171 is a novel and selective NOX1 inhibitor with IC50 value of 0.25 μM for blocking NOX1-dependent ROS generation in a HEK293-NOX1 recombinant cell system.

More Information Supplier Page

ML204 50mg  | ≥99%

CSNpharm

ML204 is a selective antagonist of TRPC4 ion channel with IC50 of 0.96 μM and 2.6 μM in fluorescent and electrophysiological assays respectively.

More Information Supplier Page

ML204 25mg  | ≥99%

CSNpharm

ML204 is a selective antagonist of TRPC4 ion channel with IC50 of 0.96 μM and 2.6 μM in fluorescent and electrophysiological assays respectively.

More Information Supplier Page

ML204 10mg  | ≥99%

CSNpharm

ML204 is a selective antagonist of TRPC4 ion channel with IC50 of 0.96 μM and 2.6 μM in fluorescent and electrophysiological assays respectively.

More Information Supplier Page

ML204 5mg  | ≥99%

CSNpharm

ML204 is a selective antagonist of TRPC4 ion channel with IC50 of 0.96 μM and 2.6 μM in fluorescent and electrophysiological assays respectively.

More Information Supplier Page

ML204 100mg  | ≥99%

CSNpharm

ML204 is a selective antagonist of TRPC4 ion channel with IC50 of 0.96 μM and 2.6 μM in fluorescent and electrophysiological assays respectively.

More Information Supplier Page

ML277 25mg  | ≥99%

CSNpharm

ML277 is a potent and selective K(v)7.1 (KCNQ1) potassium channel activator with EC50 of 270 nM.

More Information Supplier Page

ML277 10mg  | ≥99%

CSNpharm

ML277 is a potent and selective K(v)7.1 (KCNQ1) potassium channel activator with EC50 of 270 nM.

More Information Supplier Page

ML277 50mg  | ≥99%

CSNpharm

ML277 is a potent and selective K(v)7.1 (KCNQ1) potassium channel activator with EC50 of 270 nM.

More Information Supplier Page

ML281 50mg  | ≥99%

CSNpharm

ML281 is a potent and selective serine/threonine kinase (STK33) inhibitor with IC50 of 14 nM. STK33 downregulation is toxic to KRAS-dependent cancer cell lines.

More Information Supplier Page

ML281 5mg  | ≥99%

CSNpharm

ML281 is a potent and selective serine/threonine kinase (STK33) inhibitor with IC50 of 14 nM. STK33 downregulation is toxic to KRAS-dependent cancer cell lines.

More Information Supplier Page

ML281 10mg  | ≥99%

CSNpharm

ML281 is a potent and selective serine/threonine kinase (STK33) inhibitor with IC50 of 14 nM. STK33 downregulation is toxic to KRAS-dependent cancer cell lines.

More Information Supplier Page

ML281 25mg  | ≥99%

CSNpharm

ML281 is a potent and selective serine/threonine kinase (STK33) inhibitor with IC50 of 14 nM. STK33 downregulation is toxic to KRAS-dependent cancer cell lines.

More Information Supplier Page

ML281 100mg  | ≥99%

CSNpharm

ML281 is a potent and selective serine/threonine kinase (STK33) inhibitor with IC50 of 14 nM. STK33 downregulation is toxic to KRAS-dependent cancer cell lines.

More Information Supplier Page

ML281 250mg  | ≥99%

CSNpharm

ML281 is a potent and selective serine/threonine kinase (STK33) inhibitor with IC50 of 14 nM. STK33 downregulation is toxic to KRAS-dependent cancer cell lines.

More Information Supplier Page

ML329 25mg  | ≥98%

CSNpharm

ML329 is a small molecule inhibitor of MITF which inhibits TRPM-1 promoter activity with an IC50 of 1.2 μM.

More Information Supplier Page

ML329 50mg  | ≥98%

CSNpharm

ML329 is a small molecule inhibitor of MITF which inhibits TRPM-1 promoter activity with an IC50 of 1.2 μM.

More Information Supplier Page